This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent
· inc.com · popularity 19/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at inc.com →
Summary
A groundbreaking phase 3 clinical trial reveals that a personalized mRNA vaccine from Merck and Moderna significantly cuts the risk of melanoma returning.
Found in: Inc.. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 7.